Cart

0

Stocks

“Oppenheimer: These 2 Stocks Could Double, If Not More”

“NeuBase Therapeutics (NBSE)… Are other analysts in agreement? They are. Only Buy ratings, 4 to be exact, have been issued in the last three months. Therefore, the message is clear: NBSE is a Strong Buy. Given the $16.50 average price… Continue Reading…